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The regenerative effect of Intra-
articular Injection of Autologous 
Fat Micro-Graft in Treatment of 
Chronic Knee Osteoarthritis
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and Abdullah M. Kaki
Abstract
The study started in 2010 to find the effect of autologous fat micrograft for 
osteoarthritis (OA); the result was published on normal animal’s model, in 10 
patients, then in 80 patients with knee osteoarthritis, and the current study in 
205 patients. The study was conducted at King Abdulaziz University Hospital 
(January 2012–October 2015); 80 adult patients were suffering from moder-
ate to severe knee osteoarthritis. About 10–20 mL fat micrograft was prepared 
with liposuction and injected intra-articularly into the affected knee/s. The 
results revealed that pain improvement after the fat injection during rest and 
with activity with the visual analogue scale. The Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC) indicated improvement, both in the 
three domains (pain, stiffness, and physical function) and in total. The use of 
intra-articular autologous fat micrograft is simple, safe, and effective for degen-
erative knee osteoarthritis.
Keywords: autologous fat micrograft, intra-articular injection, knee osteoarthritis, 
cartilage degeneration, regenerative therapy repair
1. Introduction
Fat grafting and its use in aesthetic and reconstructive surgeries are con-
sidered a state of art, but looking back at the history, it is just a revival in the 
techniques, which was described previously by others when Gustav Neuber 
on 1893 was the first to perform fat graft for orbital depression in human and 
Erich Lexer who is a skilled German orthopedic and plastic surgeon reported a 
variety of clinical uses of fat graft in management of knee ankylosis and fat graft 
wrapped around the tendon during tendon repair to prevent skin tendon adhe-
sion and restore gliding [1, 2].
The revolution in surgical specialty directed toward minimally invasive 
therapeutic modalities where endoscopic surgery replaced the open surgical 
operations; similarly, the recent discovery of the regenerative effect of fat micro-
graft due to presence of adipose-derived stem cells (ADSCs), cytokines, growth 
factors, pre adipocytes, and mature adipocytes led to a growing interest for the 
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use fat graft as regenerative treatment replacing the major surgical rejuvenative 
operation, and Liu et al. [3] in his major review article, which includes over 265 
clinical trials about therapeutic application of mesenchymal stem cells (MSCs) 
for common bone and joint diseases, indicated that the MSCs are considered as an 
ideal source of cell therapy for different types of diseases including bone and joint 
diseases [3–5].
In this chapter we present our experience over the current decade in man-
agement of osteoarthritis (OA) by intra-articular injection of fat micrograft 
(IAFMG), describing our approach, which was developed from the belief in 
the powerful reparative effect of autologous fat graft for damage tissue as well 
as natural lubricating effect on the joints. We started on animal model, and 
upon confirming its safety and positive regenerative effects, we applied this 
minimally invasive modality on patients with advanced and moderate chronic 
osteoarthritis with fulfillment of ethical approval requirement for the trials on 
human subjects. The satisfactory outcome of this minimally invasive modality 
indicates that intra-articular injection of fat micrograft can replace or delay 
considerably the need for the classical major joint replacement surgery (JRS), 
with its impact on the quality of life of patients and financial cost of JRS, and 
long hospitalization and absence of work when compared to our minimally 
invasive procedure [6, 7].
2. Disease characteristics
Chronic osteoarthritis is a common complex disorder affecting middle-aged 
and elderly females more than males but all races. The main risk factors are con-
stitutional, including sedentary lifestyle, obesity and aging, and genetic and local 
factors (biomechanical consequences of joint injury, joint laxity, or malalignment). 
Therefore, the stress from mechanical force plays an important critical role in the 
initiation and progression of the disease; it is also associated with chronic disease 
such as diabetes, gout, and poor diet [8–15].
Osteoarthritis is the disease of the whole joint, including the bone, cartilage, 
tendons, ligaments, synovium, and synovial fluid. Osteoarthritis mainly affects 
weight-bearing joints (i.e., knees, hips, or spine) due to chronic high stress, which 
leads to degradation of the cartilage; subchondral cysts; sclerosis, which stimulates 
new bone outgrowths (osteophytes); and synovitis leading to reduction of joint 
viscosity and lubrication with more friction, irritation, consequently more cartilage 
damage and effusion, ligament laxity and meniscal tears, and progressive narrowing 
of joint space. The usual patient presentation is joint pain, swelling, crepitus, morn-
ing joint stiffness, and, after prolonged rest, hyperthermia, progressively restricted 
movement, and major disability with deterioration in quality of life [9, 10, 16, 17].
3. Management
Management included the diagnosis of the disease and its extent based on 
clinical presenting symptoms and signs of the patient, evaluating the degree 
of pain, mobility, and functions of the diseased joint, and then utilizing the 
radiological modalities to confirm the disease and its severity with plain X-ray, 
CT scan, MRI, and other available imaging modalities; following clinical and 
radiological diagnoses, the plan of treatment is established according to the 
extent of the disease, which is ranging from nonsurgical to minimally invasive or 
major surgical procedure.
3The regenerative effect of Intra-articular Injection of Autologous Fat Micro-Graft...
DOI: http://dx.doi.org/10.5772/intechopen.88220
4. Nonsurgical therapy
Currently there is no curative intervention; all treatment modalities are directed 
toward pain control, improvement of joint mobility and functions, and avoiding 
drugs with adverse effects. Non-pharmacological management should include a 
combination approach in the form of patient education, modification of lifestyle, self-
management, weight reduction, exercise, conventional physiotherapy, electrotherapy, 
hydrotherapy, and occupational therapy to prevent excessive stress on the joint.
The pharmacological symptomatic therapies for pain control are in the form of 
nonsteroidal anti-inflammatory medications such as acetaminophen and COX-2-
specific inhibitors and topical nonsteroidal anti-inflammatory drugs. On the other 
hand, intra-articular injection of corticosteroids and viscous supplementation 
injections of hyaluronic acid improve pain and viscosity, but these pharmacological 
treatments have short-term improvement effect and are costly, and the intra-
articular injections have a risk of acute synovitis [18–23].
Recently, the intra-articular injection of platelet-rich plasma to human osteo-
arthritic joints associated with significant clinical symptomatic improvements of 
inflammation and pain and viscosity [24].
5. Surgical therapy
Surgical therapy included minor and major surgical operations, but the recent use 
of the minimally invasive surgical procedure of intra-articular injection fat micro-
graft with the contained adipose-derived stem cells, which we studied on animal 
model followed by human joints, showed very satisfactory outcome; this modality of 
treatment is the main theme of this chapter which will be discussed in details.
The minor surgical procedures include arthroscopic joint lavage debridement, 
which demonstrated short-term symptom relief with more improvement when 
combined with marrow-stimulating microfracture and drilling procedures of 
articular surface; this improvement in joint functions would postpone the need for 
knee replacement [25].
6. The major surgical procedures
On the other hand, joint replacement as major surgical intervention is reserved 
for patients with failure of other modalities and in patients with joint end-stage 
disease, as joint implants have a finite life span (~10–15 years). After that a variety 
of complications might occur such as wear particle formation, which contribute 
to loosening which required revision surgery; therefore the use of artificial joints 
in young patients (e.g., <55 years) is associated with higher revision rates of this 
operation with its associated disadvantages as being a major procedure with compli-
cations, long hospitalization, absence from work, and high cost, which indicate the 
need to develop new treatment options. Therefore tissue engineering regeneration 
offers a long-term solution for repair of the affected tissue components of the joints 
such as the bone, ligament, and knee meniscus [26–28].
7. The stem cell line therapy
Osteoarthritis is an active disease process with an imbalance between the repair 
and destruction and degeneration of joint with poor intrinsic healing power and 
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regeneration due to poor vascularization and absence of direct access to progenitor 
cells of bone marrow [29].
For many years, researchers have been seeking to understand the body’s 
ability to repair and replace the damaged tissues; these researches led them to the 
discovery of the unique mesenchymal stem cell, which is partly responsible for 
maintenance and repairing of damaged connective tissues after injury. They can 
migrate toward injured tissues, where they display trophic effects of synthesis 
of proliferative, proangiogenic, and regenerative molecules. Mesenchymal stem 
cells undergo site-specific differentiation into a variety of connective tissues 
including cartilage, bone, fat, tendon, ligament, marrow stroma, and others, 
with its reparative and regenerative effects with anti-inflammatory and immuno-
modulatory actions via direct cell-cell interaction or secretion of bioactive factors, 
resulting in differentiation, stemness maintenance, self-renewal, prevention, and 
modification of progress of the disease [17, 30–38].
Mesenchymal stem cells can be isolated from several human sources other than the 
bone marrow and fetal tissues, including adipose tissue (ADSCs) with similar phe-
notypic characteristics but different propensities in proliferation and differentiation 
potentials, and provide an abundant and easily accessible source of stem cells [39–46].
With all these properties, MSCs are considered as an ideal source of cell therapy 
for different types of diseases including bone and joint diseases as reviewed by Liu 
et al. [3] as a review article about therapeutic application of MSCs for common bone 
and joint diseases, which include over 265 clinical trials of MSCs registered with 
clinical trial for knee osteoarthritis and other joint and bone diseases; they conclude 
that MSC is a promising prospect in clinical application for bone and joint diseases, 
without any reports of post application adverse immune side effects [5].
8. Animal and human researches on uses of MSCs in joints
With the growing interest of using MSCs as biological treatment for cartilage 
repair in arthritic joint diseases on different animal models where stem cells grown 
on different media scaffolds include synthetic or natural extracellular matrix, 
implantation of stem cells into the joints is either as invasive via arthroscopy with 
possible increased risk of infection or noninvasive intra-articular injection MSCs. 
These trials are summarized in Table 1 [6, 46–59].
Animal model trial
Publication MSCs Description Intervention Outcome
Murphy et al. [46] BMC MSC and suspension of 
hyaluronan injected in goat 
OA joint
Intra-articular injection
Minimally 
invasive
+ Cartilage 
regeneration
Guo et al. [47] BMC MSCs grow on scaffolds of 
bioceramic beta-tricalcium 
phosphate via open 
arthrotomy
Invasive 
with risk of 
infection
Marked 
improvement
Hui et al. [48] BMC MSCs grow on scaffolds 
of fibrin glue by open 
arthrotomy implantation
Invasive 
with risk of 
infection
Marked 
improvement
Liu et al. [49] BMC MSCs grow on scaffolds of 
hyaluronic acid and gelatin 
by open arthrotomy
Invasive risk 
of infection
Marked 
improvement
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9. Our animal trial
Our study started as an idea on 2010, when we plan to use autologous fat micro-
graft for treatment of osteoarthritis and we started by injecting fat micrograft into 
normal hind joints of sheep to determine the safety and effects of intra-articular 
injection of autologous fat micrograft, followed by observing the animal’s activities 
in using their injected joints, and by examining any macroscopic or microscopic 
changes in the articular cartilage of the fat-injected joints compared to other similar 
Animal model trial
Publication MSCs Description Intervention Outcome
Kayakabe et al. [50] BMC MSCs grow on scaffold of 
hyaluronic gel sponge by 
open arthrotomy
Invasive 
with risk of 
infection
Marked 
improvement
Yan et al. [51] BMC MSCs grow on scaffolds 
of polylactic acid by open 
arthrotomy
Invasive 
with risk of 
infection
Marked 
improvement
Lee et al. [52] BMC MSC and suspension of 
hyaluronan in injected mini 
pig OA joint
Intra-articular injection
Minimally 
invasive
+Cartilage 
regeneration
Kuroda et al. [53] BMC MSCs grow on scaffolds 
of collagen gel by open 
arthrotomy
Invasive 
with risk of 
infection
+Cartilage 
regeneration
Black et al. [54, 55] ADMSCs Double-blinded, placebo-
controlled clinical trial 
on the effect? IN dogs 
with chronic OA of 
the coxofemoral and 
humeroradial joints
Intra-articular injection
Minimally 
invasive
Significant 
improvement
Noth et al. [56] BMC MSCs seeded on three-
dimensional biodegradable 
scaffolds
Intra-articular injection
Minimally 
invasive
+Cartilage 
regeneration
Horie et al. [57] Synovium 
MSCs
Synovium MSCs in massive 
meniscal defect knee rat 
intra-articular injection
Minimally 
invasive
Promoted 
meniscal 
regeneration
Mokbel et al. [58] BMC MSC and suspension of 
hyaluronan in donkey
Intra-articular injection
Minimally 
invasive
+Cartilage 
regeneration
Sato et al. [59] BMC MSC and suspension of 
hyaluronan in Hartley strain 
guinea pig
Intra-articular injection
Minimally 
invasive
+Cartilage 
regeneration
Moshref et al. [6] ADMSCs Intra-articular injection of 
autologous fat micrograft in 
normal sheep hind joints, 
intra-articular injection
Minimally 
invasive
Increase of 
the articular 
hyaline cartilage 
thickness
Significant 
chondrocyte 
proliferation
Table 1. 
The other animal model trial studies.
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Figure 1. 
(a–c) The control sheep H&E stain; longitudinal sections in femoral diarthrosis of left hind knee. (a) Normal 
histological structure of the articular hyaline cartilage (Hc) compact bone (Cb), spongy bone (head arrows), 
and bone marrow (*), 100×. (b, c) Flattened chondrocytes (head arrows) of the surface layer of hyaline 
cartilage followed by internal globular chondrocytes arranged in rows (arrows), 400×; 1000×.
Figure 2. 
(a–c) The treated sheep right hind knee; longitudinal sections in femoral diarthrosis H&E stain. (a) Increasing 
the thickness of the articular hyaline cartilage (Hc) layer; compact bone (arrows), spongy bone (head arrows), 
and bone marrow (*) were observed in normal view, 100×. (b) Increasing the number of chondrocytes 
(arrows), 400×. (c) Chondrocyte division, metaphase (head arrows), telophase (arrows) 1000×.
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non-injected joint of the same animal; the study confirmed the safety, without any 
associated detrimental effects, on the joint tissues. Furthermore, it had positive 
microscopic findings as there was increase of the thickness of the articular hyaline 
cartilage layer with significant proliferation of chondrocytes including different 
mitosis stages (Figures 1 and 2, Table 2). Therefore, intra-articular injection of 
fat micrograft is an ideal minimally invasive choice for joint lubrication with high 
potential healing effects.
10. Our human trial
After the successful encouraging results of our previous animal study, which dem-
onstrates the potential healing power and regenerative effect of autologous fat micro-
graft with its stem cells and all other study reports of clinical trials and publication by 
using mesenchymal stromal/stem cells for management of osteoarthritis, which offer a 
great hope for the treatment of osteoarthritic joints, we decided to evaluate the efficacy 
of fresh non-processed autologous fat micrograft with its ADSCs for management of 
osteoarthritic joints as prospective interventional clinical trial, which was conducted at 
King Abdulaziz University Hospital, Jeddah, Saudi Arabia, after obtaining the ethical 
approval from the local research and ethics committee, No. 822-12, according to latest 
vision of the Declaration of Helsinki. Over the period of 2012–2013, a preliminary 
clinical trial was conducted on 10 adult patients of both genders suffering from severe 
to moderate knee osteoarthritis with encouraging results as an effective and safe 
method for the treatment of knee osteoarthritis, then we expand the trial on 80 adult 
patients which confirm our previous finding, and then the clinical trial concluded with 
the final reporting to ethical committee on December 2016 [2, 3, 6, 7, 66].
But our work in utilizing this modality of treatment continued, and we are 
currently presenting the outcome in 205 adult patients (392 knee joints) who were 
managed and completed the required period of follow-up [7, 66, 74, 75, 77, 78].
The other studies were mainly revolving around the use of bone marrow or 
expanded adipose tissues and non-expanded autologous MSCs although some 
trials use allogenic MSCs. Most researchers focus on the use of intra-articular 
injections without the use of scaffolds or major surgeries since injections are more 
cost-effective, have little morbidity, and are a desirable way of treatment. The 
satisfactory outcome of our study over 10 years indicated that MSC treatment 
appears to be a good option for treatment of moderate to severe OA in the elderly; 
other studies reported similar results to ours in demonstrating promising prospect 
of cell therapy in many refractory diseases, including bone and joint diseases, in 
great improvement of pain, mobility, and other joint functions; these have high 
potential for clinical use in tissue engineering and regenerative and reparative 
medicine. Other studies found MSCs effective in cartilage healing; these trials are 
summarized in Table 3 [28, 70–73, 76].
Knee Joints Femoral diarthrosis Tibial diarthrosis
Control 40.90 ± 0.432
Left joints
42.72 ± 0.700
Treated 55.31 ± 0.681**
Right joint
49.10 ± 0.585*
*Significant at p ≤ 0.01.
**High significant at p ≤ 0.001.
Table 2. 
Number of chondrocytes in control and treated articular cartilage of sheep knee joints.
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11. Study guidelines and patient selection
• Patients: all patients were adult patients from both genders and were 
screened for eligibility to participate in the study; each patient underwent a 
complete medical history, a physical examination, and a full assessment of 
the joint.
Human clinical studies
Publication Type of MSCs Description Intervention Outcome
Davatchi et al. [76] BMC MSCs injected with autologous 
BMSCs intra-articularly of four 
patients
Minimally 
invasive
Marked 
improvement
Wakitani et al. [70] BMC
Human 
autologous 
culture 
expanded
MSC embedded in collagen gel 
injected into medial femoral 
condyle of 12 patients and 12 as 
control
Invasive 
with risk of 
infection
Marked 
improvement
Ohgushi et al. [71] BMC MSC seeded at ceramic ankle 
prosthesis and injected in the three-
severe arthritic ankle for patients
Invasive 
with risk of 
infection
Marked 
improvement
Centeno et al. [72] BMC MSCs injected intra-articularly 
for 46-A case report study year
Minimally 
invasive
Marked 
improvement
Buda et al. [73] BMC
Human 
autologous 
culture 
expanded
MSC and hyaluronic acid for 
20 patients (12 males and eight 
females)
Minimally 
invasive
Marked 
improvement
Pak et al. [74, 75] ADSCs MSC and hyaluronic acid, 
calcium chloride, a nanogram 
dose of dexamethasone, and 
platelet-rich plasma injected 
intra-articularly for knee 
osteoarthritis or hip osteonecrosis
Minimally 
invasive
Marked clinical 
improvement 
and cartilage 
thickening
Koh et al. [77] ADSCs
Infrapatellar 
fat pad
Autologous AMSCs from 
infrapatellar fat pad injected at intra-
articular injection for 25 patients
Minimally 
invasive
Significant 
regeneration of 
cartilage
Koh et al. [78] ADSCs
Infrapatellar 
fat pad
AMSCs autologous injection
intra-articular of 18 patients
Minimally 
invasive
Marked 
improvement
Moshref et al. [7] ADSCs Intra-articular injection of 
autologous fat micrograft for the 
treatment of knee osteoarthritis 
Preliminary trail of 10 patients
Minimally 
invasive
Significant 
clinical 
improvement
Moshref et al. [66] ADSCs Intra-articular injection of 
autologous fat micrograft for the 
treatment of knee osteoarthritis. 
80 patients and 148 joints
Minimally 
invasive
Significant 
clinical 
improvement
Moshref 
2019 (under 
consideration)
ADSCs Intra-articular injection of 
autologous fat micrograft for the 
treatment of knee osteoarthritis. 
205 patients and 392 joints
Minimally 
invasive
Significant 
clinical 
improvement
Table 3. 
The other human clinical studies.
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• Informed written consent was obtained from each patient before treatment 
after explaining to him all about the study and this modality of treatment.
• Inclusion criteria: all cases of severe to moderate knee osteoarthritis, the 
changes to be confirmed by bilateral anterior-posterior standing and lateral 
supine radiographs involving one or both knees.
• Exclusion criteria: recent knee surgery, chronic opioid intake, bleeding disor-
ders, malignant disease, congenital or traumatic deformity of the knee joint, 
and refusal of the patient to be included in the study.
• For the evaluation of patient, we used the visual analogue scale for pain 
assessment (on scale 0–10 cm line, 0 = no pain and 10 = worst imaginable pain) 
was explained to patients during the preoperative visit; visual analogue scale at 
rest and during activity was obtained.
• The Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) is a questionnaire widely used to assess the symptoms and physical 
disability associated with osteoarthritis; we used five-point Likert-type Western 
Ontario and McMaster Universities Osteoarthritis Index to collect information 
regarding the three subscales of Western Ontario and McMaster Universities 
Osteoarthritis Index. Pain (five items): while sitting or lying, walking, using 
stairs, standing, and in bed. Stiffness (two items): after first walking and later in 
the day. Physical function (17 items): standing, walking, sitting, rising from sit-
ting, stair use, bending, putting on or taking off socks, lying in bed, rising from 
bed, getting in or out of the bath, sitting on or rising from the toilet, getting in 
or out of a car, shopping, light household duties, and heavy household duties
• Anesthesia and surgical interventions were explained to the patients. A list 
of adverse effects was reviewed with the patients to allow for reporting of any 
side effect that may arise post-procedure.
12. Anesthesia
The procedures were performed under controlled local anesthesia and sedation. 
Dexmedetomidine 0.7 mcg/kg/hour was administered intravenously as a sedative 
and pain reliever. Patients were monitored for heart rate, pulse oximetry, tempera-
ture, and noninvasive blood pressure.
13. Procedures
The surgical site of liposuction was carefully chosen based on the availability 
of fat and the patients’ wishes. Liposuction was performed under complete aseptic 
technique and antibiotic coverage of cefuroxime 1.5 g IV one dose, 1 hour preop-
erative followed by 500 mg orally every 12 hours for 7 days. Fat harvesting was 
obtained using 10-hole, Olivaire blunt cannula (Pouret Medical, Clichy, France) 
with 1 mm tip attached to a 10 mL Luer-Lok syringe (Terumo, Auburn, WA, USA). 
Fifty milliliters of fat micrograft was collected and then left for thirty minutes to 
settle and separate into various layers; the upper and lower layers were removed, 
while the middle layer of fat was kept for intra-articular injection (Figure 1).  
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The surgical site was prepared and injected with 100–200 mL of tumescent solution. 
Solution was prepared by mixing 30–50 mL of 1% lidocaine and 0.5 mg (0.5 mL) 
of epinephrine in 449.5 mL of lactated ringers. The osteoarthritic knee joint was 
injected with autologous intra-articular fat micrograft 15–20 mL through the lateral 
approach according to the case in an amount that did not produce high pressure 
inside the joint and did not produce pain to the patients due to tension of the joint 
capsule.
14. Postoperative advice and care
• After operation, the patient received antibiotics at home for 1 week and on 
regular pain killer for 2 weeks and is to start walking immediately as early as 
possible and increase activity as tolerated.
• Stress the preoperative advice to reduce weight, improve diet regimen, and 
perform regular exercise especially aqua or hydrotherapy therapy to strengthen 
muscle with consequently more improvement of outcome of the procedure.
• All patients were followed up in the clinic on a regular basis every 1–2 weeks 
in the first month and then every 3 months to assess incidence of side effects, 
complications, pain evaluation, stiffness and knee function problems, and 
recurrence of pain.
• The patient was informed that the improvement will start during the first 
month and increase with time, and the maximum appreciated improvement 
at 6 months, provided he will follow the given instructions and improve the 
predisposing risk and comorbid factors.
15. Statistical analysis
IBM SPSS Statistics for Windows, Version 20 (IBM Corp., Armonk, NY USA), 
was used for data analysis. Data were presented as mean ± SD and minimum-
maximum or number and percentage (n, %) as appropriate. Wilcoxon test for 
nonparametric variables was used to compare preinjection to postinjection values. 
A probability of ≤0.05 was considered significant.
16. The current study outcome of 205 patients
In this current study, we used the same methodology and patient’s selection that 
we applied in the preliminary trial and in the main study of 80 patients indicated in 
the requested ethical approval, but in this chapter, we are presenting our experience 
in the management of 205 patients.
Table 4 showed the demographic data and the clinical characteristics of the 
patients. The median age of the patients was 61.59 years, and the body mass index 
was 35.10 kg/m2. The female patients were more than male (74.10% versus 25.90%) 
with a ratio of 2.88:1. Only five patients (2.90%) were smoking. The associated 
comorbidities were obesity (74.60%), hypertension (34.60%), diabetes mellitus 
(21.50%), hypothyroidism (6.80%), rheumatoid arthritis (4.90%), low back pain 
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Parameters Data
Age (years) 61.59 ± 10.32 (33–92)
Weight (kg) 87.25 ± 16.89 (48–164)
Height (meter) 1.56 ± 0.10 (1.14–1.86)
Body mass index (kg/m2) 35.10 ± 5.77 (22.00–50.60)
Gender
 Male 53 (25.90%)
 Female 152 (74.10%)
Smoking 5 (2.90%)
Comorbidity
 Obesity 153 (74.60%)
 Hypertension 71 (34.60%)
 Type 2 diabetes mellitus 44 (21.50%)
 Hypothyroidism 14 (6.80%)
 Rheumatoid arthritis 10 (4.90%)
 Low back pain 10 (4.90%)
 Lower limb edema 3 (1.50%)
 Hepatitis 4 (2.00%)
Data are expressed as mean ± SD (minimum-maximum) or number (%) as appropriate.
Table 4. 
Demographic and clinical characteristics of patients (n = 205).
Parameters Data
Disease duration (years) 8.00 ± 5.98 (1.00–33.00)
Knee affected
 Right knee 13 (6.30%)
 Left knee 5 (2.40%)
 Bilateral knees 187 (91.20%)
Medications
 Nonsteroidal anti-inflammatory 204 (99.50%)
 Glucosamine 18 (8.80%)
 Prednisone 10 (4.90%)
 Methotrexate 7 (3.40%)
 Relaxon 9 (4.40%)
Fat injection
 Single injection 199 (97.10%)
 Two injections 5 (2.40%)
 Three injections 1 (0.50%)
Data are expressed as mean ± SD (minimum-maximum) or number (%) as appropriate.
Table 5. 
Disease duration and treatment of patients (n = 205).
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(4.90%), hepatitis (2.00%), and lower limb edema (1.50%).
The duration of OA ranged from 1 to 33 years. The right knee was affected in 
6.30% of patients and left knee in 2.40%, while both knees were affected in 91.20% 
of the cases. 99.50% of patients used NSAID, while glucosamine was used by 8.80%, 
prednisone by 4.90%, methotrexate by 3.40%, and relaxon by 4.40%. The number of 
fat injection was single in 97.10%, twice in 2.4%, or triple in 0.50% of cases (Table 5).
VAS values were significantly higher in preinjection versus postinjection 
both during rest (8.02 ± 1.81 versus 0.69 ± 0.64, p < 0.0001) and with activity 
(9.53 ± 0.88 versus 1.46 ± 0.80, p < 0.0001) which reflected a highly significant 
improvement in OA pain (Table 6 and Figure 3).
Table 7 presented the Western Ontario and McMaster Universities Osteoarthritis 
Index before and after intra-articular fat micrograft injection. The three domains of 
WOMAC index, pain, stiffness, and physical function, were significantly lower in the 
post intra-articular fat injection period than the preinjection values. The total score 
of WOMAC test and its percentage were significantly lower in the post intra-articular 
fat injection period than the preinjection values (77.65 ± 11.84 versus 5.69 ± 4.60, 
Visual analogue 
scale
Preinjection Postinjection Significance 
(P-value)
Rest 8.02 ± 1.81 (2.00–10.00) 0.69 ± 0.64 (0.00–4.00) 0.0001
Exercise 9.53 ± 0.88 (6.00–10.00) 1.46 ± 0.80 (0.00–5.00) 0.0001
Table 6. 
Visual analogue scale values at rest and with activity before and after intra-articular fat micrograft injection.
Figure 3. 
Visual analogue scale values at rest and with activity before and after intra-articular fat micrograft injection.
Western Ontario and McMaster 
Universities Osteoarthritis Index
Preinjection Postinjection Significance 
(P-value)
Pain
1. Walking 3.85 ± 0.401 (2.00–4.00) 0.65 ± 0.52 (0.00–2.00) 0.0001
2. Stair climbing 3.95 ± 0.24 (2.00–4.00) 0.98 ± 0.40 (0.00–2.00) 0.0001
3. Nocturnal 3.36 ± 0.76 (0.00–4.00) 0.25 ± 0.50 (0.00–4.00) 0.0001
4. Rest 3.15 ± 0.79 (0.00–4.00) 0.11 ± 0.32 (0.00–1.00) 0.0001
5. Weight-bearing 3.94 ± 0.29 (2.00–5.00) 0.96 ± 0.45 (0.00–2.00) 0.0001
Stiffness
6. Morning stiffness 3.103 ± 0.89 (0.00–4.00) 0.20 ± 0.40 (0.00–1.00) 0.0001
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Western Ontario and McMaster 
Universities Osteoarthritis Index
Preinjection Postinjection Significance 
(P-value)
7. Stiffness occurring later in the day 2.04 ± 1.17 (0.00–4.00) 0.14 ± 0.35 (0.00–1.00) 0.0001
Physical function
8. Descending stairs 3.90 ± 0.34 (2.00–4.00) 0.93 ± 0.36 (0.00–2.00) 0.0001
9. Ascending stairs 3.92 ± 0.32 (2.00–4.00) 0.94 ± 0.45 (0.00–4.00) 0.0001
10. Rising from sitting 3.28 ± 0.76 (1.00–4.00) 0.20 ± 0.47 (0.00–4.00) 0.0001
11. Standing 3.52 ± 0.69 (1.00–4.00) 0.47 ± 0.58 (0.00–4.00) 0.0001
12. Bending to floor 3.09 ± 0.86 (0.00–4.00) 0.22 ± 0.43 (0.00–2.00) 0.0001
13. Walking on flat surface 3.20 ± 0.75 (1.00–4.00) 0.21 ± 0.41 (0.00–1.00) 0.0001
14. Getting in/out of car 3.40 ± 0.80 (1.00–4.00) 0.64 ± 0.54 (0.00–2.00) 0.0001
15. Going shopping 3.87 ± 0.41 (2.00–4.00) 1.02 ± 0.52 (0.00–2.00) 0.0001
16. Putting on socks 2.62 ± 0.84 (0.00–4.00) 0.22 ± 0.41 (0.00–1.00) 0.0001
17. Lying in bed 2.80 ± 0.91 (0.00–4.00) 0.12 ± 0.32 (0.00–1.00) 0.0001
18. Taking off socks 2.16 ± 0.86 (0.00–4.00) 0.05 ± 0.22 (0.00–1.00) 0.0001
19. Rising from bed 2.86 ± 0.86 (0.00–4.00) 0.14 ± 0.34 (0.00–1.00) 0.0001
20. Getting in/out of bath 3.84 ± 0.60 (0.00–4.00) 1.17 ± 0.60 (0.00–2.00) 0.0001
21. Sitting 2.95 ± 0.78 (0.00–4.00) 0.14 ± 0.40 (0.00–3.00) 0.0001
22. Getting on/off toilet 2.65 ± 0.79 (1.00–4.00) 0.14 ± 0.36 (0.00–2.00) 0.0001
23. Heavy domestic duties 3.91 ± 0.40 (1.00–4.00) 1.15 ± 0.53 (0.00–4.00) 0.0001
24. Light domestic duties 2.35 ± 0.76 (0.00–4.00) 0.04 ± 0.22 (0.00–2.00) 0.0001
Total score
Out of 96 77.65 ± 11.84 
(32.00–96.00)
5.69 ± 4.60 (0.00–24.00) 0.0001
Percentage (%) 80.89 ± 12.34 
(33.33–100.00)
5.93 ± 4.79 (0.00–25.25) 0.0001
The activities in each category are rated according to the following scale of difficulty: 0 = none; 1 = slight; 2 = moderate; 
3 = very; 4 = extremely. Data are expressed as mean ± SD (minimum-maximum). Wilcoxon test for nonparametric 
variables was used to compare pre- to postinjection values.
Table 7. 
The Western Ontario and McMaster Universities Osteoarthritis Index before and after intra-articular fat 
micrograft injection.
Figure 4. 
The Western Ontario and McMaster Universities Osteoarthritis Index Pain before and after intra-articular fat 
micrograft injection.
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Figure 5. 
The Western Ontario and McMaster Universities Osteoarthritis Index Stiffness before and after intra-articular 
fat micrograft injection.
Figure 6. 
The Western Ontario and McMaster Universities Osteoarthritis Index Physical activity before and after intra-
articular fat micrograft injection.
Figure 7. 
The Western Ontario and McMaster Universities Osteoarthritis Index Total Score before and after intra-
articular fat micrograft injection.
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p < 0.0001; 80.89 ± 12.34 versus 5.93 ± 4.79, p < 0.0001) (Table 7 and Figures 4–7).
Wilcoxon test for nonparametric variables was used to compare pre- to postin-
jection values.
17. Complications
We did have complication like infection or graft rejection; it was well tolerated 
because it is autologous.
18. Conclusion
Over 10 years our clinical study of treatment of chronic osteoarthritis using 
intra-articular injection of autologous fat micrograft offers an effective and safe 
treatment as a nonantigenic, lubricating, regenerative, and reparative modality 
which helps to restore the damaged cartilages and in turn improve joint pain, 
mobility, and other functions of the osteoarthritic joints; it is minimally invasive, 
without scars, and with lower cost than other lines of therapy, improves the quality 
of life, and is mostly effective with single injection, but reinjection is needed in 
some patients according to disease severity and chronicity. We found a selection of 
patients and preoperative correction of risk factors, e.g., obesity muscle weakness 
led to better outcome of the procedure.
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